I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 22 2004 Signature:

Docket No.: EGYP 3.9-030 CONT (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Gérard Quentin

Confirmation Number 2993

Application No.: 10/751,601

Group Art Unit:

Filed: January 5, 2004

Examiner:

For: NOVEL CHROMOGENIC SUBSTANCES AND

USE THEREOF FOR THE DETERMINATION OF

CARBOXYPEPTIDASE ACTIVITIES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. The cited references were listed on the search report issued in connection with applicant's corresponding French application. A copy of each reference and a copy of the French search report are enclosed. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: June 22, 2004

Respectfully submitted,

Michael H. Teschner

Registration No.: 32,862

LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK, LLP

600 South Avenue West Westfield, New Jersey 07090

(908) 654-5000

Attorney for Applicant

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

de to respond to a delication of information differs it contains a valid Civil Contain number				
Complete if Known				
Application Number	10/751,601 January 5, 2004			
Filing Date				
First Named Inventor	Gérard Quentin			
Art Unit				
Examiner Name				
Attorney Docket Number	EGYP 3.9-030 CONT			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	CA	MOCK and XU, "Catalytic activity of carboxypeptidase B and of Carboxypeptidase Y with anisylazoformyl substrates," Bioorganic & Medicinal Chemistry Letters, Vol. 9, pgs 187-192 (1999)/			
	СВ	MOCK et al., "Arazoformyl peptide surrogates as spectrophotometric kinetic assay substrates for carboxypeptidase A," Analytical Biochemistry, Vol. 239, pgs 218-222 (1996).			
	СС	MOCK and STANFORD, "Arazoformyl dipeptide substrates for thermolysin. Confirmation of a reverse protonation catalytic mechanism," Biochemistry Vol 35 No. 23 pgs 7369-77 (1996).			
	CD	SCHATTEMAN et al., "Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma," Clinical Chemistry Vol. 45, No. 6 pgs 807-13 (1999).			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.